Loading...
•
Sep 30, 2025
Pennant Group Q3 2025 Earnings Report
Pennant Group reported its third quarter 2025 results, showcasing record-breaking performance across its segments and significant revenue growth.
Key Takeaways
The Pennant Group achieved record-breaking performance in the third quarter of 2025, with total revenue reaching $229.0 million, a 26.8% increase year-over-year. The company reported GAAP diluted earnings per share of $0.17 and adjusted diluted earnings per share of $0.30. Net income was $6.1 million, while adjusted net income saw a substantial increase of 27.6% to $10.4 million. This strong performance was driven by growth in both Home Health and Hospice Services and Senior Living Services segments, along with key acquisitions.
Total revenue for Q3 2025 increased by 26.8% to $229.0 million compared to the prior year quarter.
GAAP diluted EPS was $0.17, and adjusted diluted EPS was $0.30 for the third quarter.
Net income for the quarter was $6.1 million, while adjusted net income grew by 27.6% to $10.4 million.
The company completed a significant acquisition of 54 home health, hospice, and home care operations on October 1, expanding its presence into the Southeast.
Revenue by Segment
Forward Guidance
Management has provided updated 2025 annual guidance, anticipating total revenue between $911.4 million and $948.6 million, adjusted earnings per diluted share between $1.14 and $1.18, and adjusted EBITDA between $70.9 million and $73.8 million. This guidance reflects continued strong operational performance and the impact of recent acquisitions.
Positive Outlook
- Updated earnings guidance midpoint of $1.16 represents 23.4% growth over 2024 adjusted EPS.
- Guidance is based on continued strong operational performance across all segments.
- Includes additional revenue from the acquisition of 54 home health, hospice, and home care operations from UnitedHealth Group and Amedisys.
- Management believes providing updated annual adjusted consolidated EBITDA guidance is helpful for understanding business expectations and operational cash flow.
- The company is well-positioned to effectively transition and unlock additional potential in the newly acquired assets and further expansion in the region.
Challenges Ahead
- The newly acquired UnitedHealth and Amedisys assets will be in a transitional phase during the fourth quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...